Author:
Ho Kerrie-Anne,Pierce Anna,Stoltenberg Meredin,Tarancon Thais,Mansfield Carol
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference14 articles.
1. Ho M, Saha A, McCleary KK, Levitan B, Christopher S, Zandlo K, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. Value Health. 2016;19(6):746–50. https://doi.org/10.1016/j.jval.2016.02.019.
2. US FDA. Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications. Guidance for Industry and Food and Drug Administration Staff. 2019. Available at: https://www.fda.gov/media/99769/download. Accessed 27 Dec 2022.
3. Marsh K, van Til JA, Molsen-David E, Juhnke C, Hawken N, Oehrlein EM, et al. Health preference research in Europe: a review of its use in marketing authorization, reimbursement, and pricing decisions-report of the ISPOR stated preference research special interest group. Value Health. 2020;23(7):831–41. https://doi.org/10.1016/j.jval.2019.11.009.
4. Soekhai V, Whichello C, Levitan B, Veldwijk J, Pinto CA, Donkers B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(7):1324–31. https://doi.org/10.1016/j.drudis.2019.05.001.
5. van Overbeeke E, Janssens R, Whichello C, Schölin Bywall K, Sharpe J, Nikolenko N, et al. Design, conduct, and use of patient preference studies in the medical product life cycle: a multi-method study. Front Pharmacol. 2019;10:1395. https://doi.org/10.3389/fphar.2019.01395.